CytoMed Therapeutics Ltd., a clinical-stage biopharmaceutical company based in Singapore, has announced its expansion into the field of autoimmune diseases following its acquisition of a cord blood bank. The company has successfully scaled natural killer (NK) cells from cryopreserved cord blood units, setting the stage for establishing a new business platform aimed at generating additional revenue and future growth. Under its restructured group, LongevityBank Pte Ltd will focus on autologous therapies, capitalizing on personalized cellular banking services. Meanwhile, CytoMed will continue to develop donor blood-derived allogeneic therapies, with ongoing clinical trials in Singapore and India. The strategic move positions LongevityBank to potentially spin off as an independent biopharmaceutical entity, concentrating on cord blood-derived treatments for autoimmune conditions. CytoMed anticipates that this expansion will contribute positively to its revenue, leveraging Asia's cost-effective R&D and manufacturing capabilities.